Watch for topline Part C data in Q4 2026, which will inform Phase 2b dose selection and potential partnership or financing needs. Positive safety and PK data could validate higher dosing and de-risk future development, but lack of funding clarity introduces execution risk.
SKYE drugs
SKYE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 2 $0.6980entry
- T+1 · 8mo ago +2.29%α +1.82% · $0.7140
- T+5 · 7mo ago +3.15%α −0.47% · $0.7200
- T+20 · 7mo ago +25.93%α +16.05% · $0.8790
- T+60 · 5mo ago −0.67%α −14.83% · $0.6933
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Skye Bioscience has dosed the first patient in the Part C expansion of its Phase 2a trial for nimacimab, testing higher IV doses (400 mg and 600 mg) to evaluate improved peripheral exposure and safety. The company highlighted strong prior results from combination therapy with semaglutide, showing 22.3% mean weight loss at 52 weeks, and received FDA feedback on its proposed Phase 2b design, though trial progression depends on Part C data and capital availability.
Key Facts
- First patient dosed in Part C expansion study of nimacimab Phase 2a trial, testing 400 mg IV and 600 mg IV doses.
- Higher doses correspond to ~700 mg and ~1,000 mg subcutaneous dosing, aiming for greater peripheral tissue exposure.
- Prior combination data with semaglutide showed 22.3% mean weight loss at 52 weeks, no plateau, and reduced weight regain off-treatment.
- No drug-related neuropsychiatric adverse events reported in any arm through full study period.
- Topline data from Part C expected in Q4 2026; Phase 2b trial design contingent on results, regulatory input, and funding.
Financial Impact
No immediate financial impact disclosed; future trial progression dependent on capital availability.
Risk Factors
- Development is contingent on capital availability, risk of delay or halt if financing is not secured.
- Higher dosing may compromise the CNS-sparing safety profile, undermining nimacimab’s key differentiator.
- Enrollment in higher-dose cohort depends on safety review, creating binary risk at early stage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3267226 |
Track record
16 reports on SKYE
5 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +82.80% at T+60 after the Aug 14, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago DEFA14A Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
- Oct 26, 202621d ago PREM14A Bearish 7/10 Entry $1.45 Now $1.07 +26.55% settles Nov 24
- Oct 14, 20264w ago SC 13G Neutral 4/10 Entry $1.59 to $1.08 Now $1.07 −33.02% ▼ −32.08% −30.17% vs SPY
- Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $1.67 to $1.54 Now $1.07 −36.23% ▼ −7.78% −6.31% vs SPY
- Sep 24, 20267w ago SC 13D/A Bearish 6/10 Entry $1.67 to $1.54 Now $1.07 +36.23% ▲ +7.78% +6.31% vs SPY
- Sep 18, 20268w ago Insider Cluster Bearish 4/10 Entry $1.78 to $1.53 Now $1.07 +40.17% ▲ +14.04% +13.14% vs SPY
- Aug 19, 202612w ago DEFA14A Neutral 4/10 Entry $0.2809 to $0.2206 Now $1.07 +279.14% ▼ −21.46% −21.34% vs SPY
- Aug 14, 202613w ago 8-K Mixed 7/10 Entry $0.5015 to $0.2487 Now $1.07 +112.36% ▼ −50.40% −48.41% vs SPY
- Aug 14, 202613w ago Press Release Bearish 7/10 Entry $0.5015 to $0.2487 Now $1.07 −112.36% ▲ +50.40% +48.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers